SCHEDULE: Vanguard Trims Inovio Stake Below 5%

The Vanguard Group has reduced its beneficial ownership in Inovio Pharmaceuticals Inc. to 4.96% as of December 31, 2025, triggering an amended Schedule 13G filing.

Summary

• The Vanguard Group reported beneficial ownership of 3,315,579 shares of Inovio Pharmaceuticals Inc. common stock as of December 31, 2025.
• This represents 4.96% of Inovio Pharmaceuticals Inc.'s class of securities, falling below the 5% reporting threshold.
• Vanguard holds shared voting power over 422,301 shares and shared dispositive power over all 3,315,579 shares.
• This filing is an Amendment No. 1 to a previous Schedule 13G, indicating a change in ownership from a prior report.
• An internal realignment at The Vanguard Group, effective January 12, 2026, means it no longer performs portfolio management or administers proxy voting, with subsidiaries expected to report beneficial ownership separately in the future.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative signal due to the reduction of a major institutional investor's stake below the 5% reporting threshold, although Vanguard still maintains a substantial holding.

Positives

• The Vanguard Group, a significant institutional investor, continues to hold a substantial stake (4.96%) in Inovio Pharmaceuticals Inc., indicating ongoing institutional interest.

Negatives

• The reduction of Vanguard's stake below the 5% threshold suggests a decrease in their overall position, which could be interpreted as a negative signal by the market.

Future Outlook

The Vanguard Group anticipates that certain subsidiaries or business divisions will report beneficial ownership separately from The Vanguard Group, Inc. in reliance on SEC Release No. 34-39538, following an internal realignment effective January 12, 2026.

Industry Context

StockSavvy.ai notes that Schedule 13G filings provide transparency into significant institutional ownership, offering insights into major investors' positions. A reduction below the 5% threshold, as seen with Vanguard's stake in Inovio, often signals a shift in an institutional investor's strategy or outlook on the company, potentially influencing other market participants.

Stakeholder Impact

• Shareholders: Existing shareholders might view the reduction in Vanguard's stake as a negative signal, potentially impacting investor confidence and share price.
• Investment Community: The filing provides transparency regarding institutional holdings, informing other investors about major shifts in ownership.

Next Steps

• Vanguard's subsidiaries or business divisions are expected to report beneficial ownership separately in the future.

Key Dates

Recommendation

While The Vanguard Group has reduced its stake below the 5% threshold, indicating a potential shift in their investment strategy, they still maintain a significant holding of 4.96%. This suggests continued, albeit reduced, institutional interest. Without further information on Inovio's operational performance or Vanguard's specific reasons for the reduction, a 'hold' recommendation is prudent, advising investors to monitor future developments rather than making immediate buy or sell decisions based solely on this ownership change.

Keywords

Inovio Pharmaceuticals, Vanguard Group, Beneficial Ownership, Schedule 13G, Institutional Ownership, Stock Holdings, Equity Stake, 45773H409